全文获取类型
收费全文 | 11241篇 |
免费 | 643篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 221篇 |
妇产科学 | 309篇 |
基础医学 | 1430篇 |
口腔科学 | 449篇 |
临床医学 | 902篇 |
内科学 | 2797篇 |
皮肤病学 | 134篇 |
神经病学 | 952篇 |
特种医学 | 457篇 |
外科学 | 1882篇 |
综合类 | 34篇 |
预防医学 | 486篇 |
眼科学 | 122篇 |
药学 | 671篇 |
中国医学 | 31篇 |
肿瘤学 | 1005篇 |
出版年
2024年 | 8篇 |
2023年 | 84篇 |
2022年 | 229篇 |
2021年 | 383篇 |
2020年 | 222篇 |
2019年 | 325篇 |
2018年 | 400篇 |
2017年 | 275篇 |
2016年 | 329篇 |
2015年 | 390篇 |
2014年 | 592篇 |
2013年 | 650篇 |
2012年 | 951篇 |
2011年 | 961篇 |
2010年 | 518篇 |
2009年 | 499篇 |
2008年 | 759篇 |
2007年 | 775篇 |
2006年 | 639篇 |
2005年 | 640篇 |
2004年 | 638篇 |
2003年 | 508篇 |
2002年 | 410篇 |
2001年 | 62篇 |
2000年 | 48篇 |
1999年 | 68篇 |
1998年 | 72篇 |
1997年 | 70篇 |
1996年 | 56篇 |
1995年 | 51篇 |
1994年 | 57篇 |
1993年 | 50篇 |
1992年 | 27篇 |
1991年 | 36篇 |
1990年 | 26篇 |
1989年 | 25篇 |
1988年 | 23篇 |
1987年 | 15篇 |
1986年 | 18篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1974年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
Carlo Gambacorti-Passerini Massimo Zucchetti Domenico Russo Roberta Frapolli Magda Verga Silvia Bungaro Lucia Tornaghi Fabio Rossi Pietro Pioltelli Enrico Pogliani Daniele Alberti Gianmarco Corneo Maurizio D'Incalci 《Clinical cancer research》2003,9(2):625-632
PURPOSE: Imatinib (Glivec) is a potent inhibitor of bcr/abl, an oncogenic fusion protein that causes chronic myelogenous leukemia (CML). alpha1 acid glycoprotein (AGP) binds to imatinib with high affinity and inhibits imatinib activity in vitro and in vivo in an animal model. A pharmacokinetics analysis of imatinib was undertaken in CML patients. EXPERIMENTAL DESIGN: Imatinib plasma concentrations were measured in 19 CML patients treated with imatinib (400 or 600 mg/day). Five patients received a concomitant short-term course of clindamycin (CLI). RESULTS: A positive correlation between AGP and imatinib plasma levels was observed. CLI administration decreased imatinib plasma concentrations, evaluated as area under the curve (AUC) and peak concentrations (C(max)). The effects of a bolus of CLI was studied in three patients on imatinib 23 h after the last imatinib dose. Within 5-10 min in three of three cases, CLI caused a decrease in imatinib plasma concentrations of 2.6-, 2.7-, and 4.7-fold, respectively. In vitro experiments using fresh blasts from CML patients showed that AGP, at concentrations observed in the patients, decreased imatinib intracellular concentrations up to 10 times and blocked imatinib activity. The incubation with CLI restored imatinib intracellular concentrations and biological activity. CONCLUSION: AGP exerts significant effects of the pharmacokinetics, plasma concentrations, and intracellular distribution of imatinib in CML patients; these data indicate that plasma imatinib levels represent unreliable indicators of the cellular concentrations of this molecule. 相似文献
82.
83.
Tiziano Maggino M.D. Cesare Romagnolo M.D. Fabio Landoni M.D. Enrico Sartori M.D. Paolo Zola M.D. Angiolo Gadducci M.D. 《Gynecologic oncology》1998,68(3):274-279
Objective.The aim of this study was to define the clinical–therapeutical approach to endometrial cancer now being followed in some of the most important centers of reference for gynecological cancer in North America by means of a questionnaire.Study design.The questionnaire focused on four principal areas: (1) surgical staging and therapy; (2) adjuvant treatment; (3) treatment modifications; and (4) management of advanced stages (FIGO III–IV).Results.There were 48 evaluable responses (77%) received by the end of December 1994 which were considered for this analysis. Lymphadenectomy is utilized routinely in 26/48 centers (54.2%) and in selective clinical–pathological conditions in another 21/48 centers (43.5%). In the majority of centers (31/48; 64.6%) radical surgery is utilized for selected indications such as cervical involvement. Only 3/48 (6.2%) centers consider the vaginal approach totally inappropriate. The great majority (40/48; 83.3%) of the centers considered postsurgical adjuvant therapy to be necessary in FIGO Stage Ic. Brachytherapy is routinely performed in 3 centers (6.2%) in postsurgical management of Stage I endometrial cancer, while the majority of the centers (31/48; 64.6%) perform brachytherapy of the vaginal vault in certain clinical–pathological conditions. A wide variety of treatments are used for advanced stages (FIGO III–IV).Conclusions.It emerges that some controversial aspects exist on endometrial cancer treatment, and these conflicting data need a large-scale multicenter randomized clinical trial. 相似文献
84.
85.
Fernando Pretel Rute M Gon?alves-de-Andrade Fabio Carlos Magnoli Maria Esther R da Silva Jorge M C Ferreira Carmen W van den Berg Denise V Tambourgi 《Toxicon》2005,45(4):449-458
Loxosceles adelaida spiders (Araneae, Sicariidae) are found near and inside the caves in the Parque Estadual Turistico do Alto Ribeira (PETAR), Sao Paulo, Brazil, which are visited by thousands of tourists every year. Several Loxosceles species are a public health problem in many regions of the world, by causing severe dermonecrosis and/or complement dependent haemolysis upon envenomation. The aim of this study was to characterize the biochemical and biological properties of L. adelaida venom and evaluate the toxic potential of envenomation by this non-synanthropic Loxosceles species. The biological activities of the L. adelaida venom was compared to that of Loxosceles gaucho, a synanthropic species of medical importance in Brazil. L. adelaida venom showed a similar potential to induce haemolysis, dermonecrosis and lethality as L. gaucho venom. L. adelaida crude venom was purified, yielding a 31 kDa component endowed with haemolytic and dermonecrotic activities. In conclusion, we show here that the troglophile Loxosceles species, L. adelaida, commonly found in the complex of caves from PETAR, is potentially able to cause envenomation with the same gravity of those produced by synanthropic species. 相似文献
86.
We conducted a meta-analysis of randomized controlled clinical trials on steroid treatment for multiple sclerosis and optic
neuritis. Of the 25 trials comparing steroids and controls without steroid treatment that we identified 12 were selected for
this review. A meta-analysis was conducted to calculate the overall odds ratio across the studies for the numbers of patients
without functional improvement and with new relapses. The trials included a total of 1714 patients: 998 with multiple sclerosis
and 716 with optic neuritis. Any type of corticosteroids or adrenocorticotropic hormone (ACTH) treatment was considered, as
was any dosage, route of administration, and length of treatment. Main outcome measures were: (a) number of multiple sclerosis
patients who did not improve by at least one point on the EDSS or equivalent scale, or number of optic neuritis patients without
complete recovery of visual acuity at 8 or 30 days and at longer follow-up; (b) number of multiple sclerosis patients with
at least one new relapse, or number of optic neuritis patients in whom definite multiple sclerosis was diagnosed at longer
follow-up. We found that corticosteroids or ACTH produced a significant improvement in disability or visual acuity at 30 days
(odds ratio 0.49; 95 % CI 0.37–0.64). The improvement was not statistically significant at longer follow-up (0.85; 95 % CI
0.67–1.09). The treatment did not significantly reduce the number of patients with relapses (0.74; 95 % CI 0.54–1.01). Both
low and high doses were effective for 30-day improvement, but only high-dose and short-term therapy were factors that identified
subgroups with some reduction in the risk of new relapse. However, the power of the statistical analysis to detect a reliable
difference in the subgroups was low. Steroid treatment is therefore effective in accelerating short-term recovery in patients
with multiple sclerosis or optic neuritis. Whether steroids are also effective in reducing the risk of relapse, and the optimal
dose and length of treatment must still be determined.
Received: 5 August 1999, Received in revised form: 29 December 1999, Accepted: 22 January 2000 相似文献
87.
Fabio Scopesi Silvana Canini Cesare Arioni Massimo Mazzella Diego Gazzolo Pasquale B Lantieri Wanda Bonacci Giovanni Serra 《The journal of maternal-fetal & neonatal medicine》2006,19(6):343-346
BACKGROUND: Recently we demonstrated an increased 2,3-diphosphoglycerate (2,3-DPG) erythrocyte concentration in rat pups subjected to nucleotide-enriched artificial feeding. DESIGN: The present study was carried out to test the hypothesis that a possible increase in 2,3-DPG concentration can also be obtained in human neonates who are fed nucleotide-enriched formula. Preterm neonates born or referred to the neonatal intensive care unit of the G. Gaslini Hospital, Genoa University, with a gestational age >30 weeks and <37 weeks were enrolled in our randomized trial. Recruitment took place within 48-72 hours from birth. Only newborns of mothers deciding not to breast-feed were eligible to be randomized for the supplemented group (FN) or non-supplemented group (RF). Breast-fed newborns were considered the control group (C). The study window (for supplementation and blood samples) was restricted to the first two weeks following birth (from the 2nd (t1) to the 16th (t2) day of life). At the end of our study, only 21 neonates were eligible for statistical analysis. RESULTS: The stimulating action of dietary nucleotides on 2,3-DPG concentration failed to be demonstrated; increases in 2,3-DPG concentration that were observed in newborns fed with nucleotide supplemented formula (FN) were comparable to those observed in newborns fed with regular formula (RF) and breast-fed newborns. CONCLUSIONS: The EC recommendation for the amount of nucleotides allowed in formula milk does not seem to be high enough to have positive effects on 2,3-DPG synthesis. Whether this possible 'pharmacological' effect can be achieved by a higher intake of ingested nucleotides and/or a change in the proportions of single nucleotides contained in milk formulas remain interesting end points to be elucidated. 相似文献
88.
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 总被引:1,自引:0,他引:1
89.
90.
Andra Araujo Brando Weimar Kunz Sebba Barroso Audes Feitosa Eduardo Costa Duarte Barbosa Roberto Dischinger Miranda Priscila Valverde de Oliveira Vitorino Roberto Pozzan Lucio Paulo Ribeiro Abraham Epelman Giovanni Alves Saraiva Fabio Serra Silveira Antnio Almeida Braga Marco Mota Gomes 《Arquivos brasileiros de cardiologia》2022,119(2):353